Middle East & Africa Cardiac Biomarkers Market Size & Outlook

The cardiac biomarkers market in Middle East & Africa is expected to reach a projected revenue of US$ 1,675.1 million by 2030. A compound annual growth rate of 8.6% is expected of Middle East & Africa cardiac biomarkers market from 2025 to 2030.
Revenue, 2024 (US$M)
$1,024.6
Forecast, 2030 (US$M)
$1,675.1
CAGR, 2025 - 2030
8.6%
Report Coverage
Middle East & Africa

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Middle East & Africa cardiac biomarkers market, 2018-2030 (US$M)

Middle East & Africa cardiac biomarkers market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

MEA cardiac biomarkers market highlights

  • The MEA cardiac biomarkers market generated a revenue of USD 1,024.6 million in 2024.
  • The market is expected to grow at a CAGR of 8.6% from 2025 to 2030.
  • In terms of segment, troponin was the largest revenue generating type in 2024.
  • Troponin is the most lucrative type segment registering the fastest growth during the forecast period.
  • Country-wise, UAE is expected to register the highest CAGR from 2025 to 2030.

MEA data book summary

Market revenue in 2024USD 1,024.6 million
Market revenue in 2030USD 1,675.1 million
Growth rate8.6% (CAGR from 2025 to 2030)
Largest segmentTroponin
Fastest growing segmentTroponin
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationTroponin, CK-MB, Myoglobin, BNP and NT-proBNP
Key market players worldwideAbbott Laboratories, QuidelOrtho Corp, Siemens Healthineers AG ADR, Roche Holding AG ADR, Danaher Corp, BioMerieux SA, Bio-Rad Laboratories Inc, Randox, Creative Diagnostics, Life Diagnostics

Other key industry trends

  • In terms of revenue, MEA region accounted for 4.4% of the global cardiac biomarkers market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 12,541.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cardiac Biomarkers Market Companies

Name Profile # Employees HQ Website
Life Diagnostics View profile 1-10 West Chester, Pennsylvania, United States, North America http://lifediagnostics.com
Randox View profile 1001-5000 Crumlin, Antrim, United Kingdom, Europe http://www.randox.com
Creative Diagnostics View profile 51-100 New York, New York, United States, North America http://www.creative-diagnostics.com
Bio-Rad Laboratories Inc View profile 8030 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 https://www.bio-rad.com
QuidelOrtho Corp View profile 7100 9975 Summers Ridge Road, San Diego, CA, United States, 92121 https://www.quidelortho.com
Danaher Corp View profile 63000 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 https://www.danaher.com
Siemens Healthineers AG ADR View profile 71400 Siemensstr. 3, Forchheim, BY, Germany, 91301 https://www.siemens-healthineers.com
BioMerieux SA View profile 13982 Marcy l’Etoile, Lyon, France, 69280 http://www.biomerieux.com
Abbott Laboratories View profile 114000 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 https://www.abbottinvestor.com
Roche Holding AG ADR View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com

Middle East & Africa cardiac biomarkers market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac biomarkers market will help companies and investors design strategic landscapes.


Troponin was the largest segment with a revenue share of 38.82% in 2024. Horizon Databook has segmented the Middle East & Africa cardiac biomarkers market based on troponin, ck-mb, myoglobin, bnp and nt-probnp covering the revenue growth of each sub-segment from 2018 to 2030.


According to the data from the World Health Organization (WHO), an estimated three-quarters of the global mortality stemming from CVDs occur in low and middle-income countries. In Africa, CVDs in the form of heart attacks and heart failure are common. Recent developments in health research conducted on the African continent have led to improvements in the detection and treatment of cardiac disorders.

Optimization of resources and the implementation of new healthcare systems are expected to rise, which is expected to benefit the cardiac diagnostics area, especially the development of cardiac biomarkers used for the detection and evaluation of cardiac diseases. 

Reasons to subscribe to Middle East & Africa cardiac biomarkers market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa cardiac biomarkers market databook

  • Our clientele includes a mix of cardiac biomarkers market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cardiac biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cardiac biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

MEA cardiac biomarker market size, by country, 2018-2030 (US$M)

Middle East & Africa Cardiac Biomarkers Market Outlook Share, 2024 & 2030 (US$M)

MEA cardiac biomarker market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online